Janet Helen Roberts

Dr. Janet Helen Roberts

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Autoimmunity Reviews
Verified
Journal Article
Closed access
JRJanet Helen Roberts
Janet Helen Roberts
DEDaniel Ennis
Daniel Ennis
MHMarie Hudson
Marie Hudson
CYCarrie Ye
Carrie Ye
ASAlexandra Saltman
Alexandra Saltman
SJShahin Jamal
Shahin Jamal

30 January 2019 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
JRJanet Helen Roberts
Janet Helen Roberts
MSMichael Smylie
Michael Smylie
JWJohn Walker
John Walker
NBNaveen S. Basappa
Naveen S. Basappa
QCQuincy Chu
Quincy Chu
CYCarrie Ye
Carrie Ye

1 February 2022 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
SKStephanie C Kulhawy-Wibe
Stephanie C Kulhawy-Wibe
JWJessica Widdifield
Jessica Widdifield
JLJennifer J Y Lee
Jennifer J Y Lee
JTJ Carter Thorne
J Carter Thorne
EYElaine Yacyshyn
Elaine Yacyshyn
CBClaire E H Barber
Claire E H Barber
Objective.: The Canadian Rheumatology Association (CRA) launched the Workforce and Wellness Survey to update the Canadian rheumatology workforce characteristics.Methods.: The survey included demographic and practice information, pandemic effects, and the Mini Z survey to assess burnout. French and English survey versions were distributed to CRA members electronically between October 14, 2020, and March 5, 2021. The number of full-time equivalent (FTE) rheumatologists per 75,000 population was estimated from the median proportion of time in clinical practice multiplied by provincial rheumatologist numbers from the Canadian Medical Association.Results.: Forty-four percent (183/417) of the estimated practicing rheumatologists (149 adult; 34 pediatric) completed the survey. The median age was 47 years, 62% were female, and 28% planned to retire within the next 5–10 years. Respondents spent a median of 65% of their time in clinical practice. FTE rheumatologists per 75,000 population were 0.62 nationally and ranged between 0.00 and 0.70 in each province/territory. This represents a deficit of 1–78 FTE rheumatologists per province/territory and 194 FTE rheumatologists nationally to meet the CRA’s workforce benchmark. Approximately half of survey respondents reported burnout (51%). Women were more likely to report burnout (OR 2.86, 95% CI 1.42–5.93). Older age was protective against burnout (OR 0.95, 95% CI 0.92–0.99). As a result of the pandemic, 97% of rheumatologists reported spending more time engaged in virtual care.Conclusion.: There is a shortage of rheumatologists in Canada. This shortage may be compounded by the threat of burnout to workforce retention and productivity. Strategies to address these workforce issues are needed urgently.

8 December 2024 in Immunotherapy
Verified
Journal Article
Closed access
JRJanet Helen Roberts
Janet Helen Roberts
SBSara Barmettler
Sara Barmettler
JMJenna Murray
Jenna Murray
JMJennifer E. Melvin
Jennifer E. Melvin
CYCarrie Ye
Carrie Ye
Immune checkpoint inhibitors (ICIs) are first-line treatment for melanoma. The incidence of musculoskeletal immune-related adverse events (MSK irAEs) remains unclear. To estimate the relative risk of MSK irAEs in melanoma patients treated with ICIs targeting programmed cell death-1 or its ligand PD-(L)1 as compared to placebo. We performed a systematic literature review including phase III randomized controlled trials of adult melanoma patients comparing a PD-(L)1 inhibitor to a placebo arm. Outcomes of interest included arthralgias, arthritis, back pain and myalgias. Meta-analysis was performed to estimate the pooled relative risk of MSK irAEs over the treatment course. Four RCTs met the inclusion criteria (n = 3,041 subjects). Use of PD-(L)1 inhibitors was associated with an increased risk of developing arthralgias (RR 1.30 [95% CI: 1.13-1.49]) and myalgias (RR 1.48 [95% CI: 1.17-1.87]) as compared to placebo. Back pain and arthritis were not reported. Use of PD-(L)1 inhibitors is associated with a significantly increased risk of arthralgias and myalgias in melanoma patients. The risk of back pain and arthritis is unknown. MSK irAEs can impact quality of life and should be considered, particularly in the adjuvant setting when risks and benefits are carefully weighed.

15 September 2025 in The Journal of Rheumatology
Verified
Journal Article
Open access
PDF file
CYCarrie Ye
Carrie Ye
RNRoko P.A. Nikolic
Roko P.A. Nikolic
MCMay Choi
May Choi
AFAurore Viviane Fifi-Mah
Aurore Viviane Fifi-Mah
JGJeffrey Graham
Jeffrey Graham
SJShahin Jamal
Shahin Jamal
Objective: Although immune checkpoint inhibitors (ICIs) are increasingly used in patients with preexisting systemic autoimmune rheumatic diseases (SARDs), a key concern is whether baseline immunosuppression at the start of ICI treatment might negatively affect cancer outcomes. This risk must be carefully weighed against the potential for a SARD flare. The objective of this study was to develop a living guideline that will provide up-to-date guidance on the management of baseline immunosuppression for preexisting SARDs when initiating cancer immunotherapy with ICIs. Methods: The Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO) formed a multidisciplinary panel composed of rheumatologists, oncologists, researchers, and a patient representative, with methodological support from the Canadian Rheumatology Association (CRA). We completed a systematic literature review to inform this first installment of our living guideline. Using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach, the panel developed recommendations for the management of baseline immunosuppression in individuals with preexisting SARDs. Results: We identified 67 publications that reported on immunosuppression and cancer outcomes by specific preexisting rheumatic diseases, including 36 on preexisting SARD. Eight best practice statements were developed, highlighting the importance of shared decision making between patients and their care team and careful consideration of risk of SARD flare, risk of organ- or life-threatening manifestations, and potential effect of immunosuppression on cancer outcomes. Seven specific recommendations were made, 1 each for preexisting systemic lupus erythematosus, systemic sclerosis, Sjögren disease, myositis, sarcoidosis, vasculitis, and Behçet disease, considering both the available evidence and expert consensus. The general recommendation for preexisting SARDs was to continue baseline immunosuppression, particularly if there are organ- or life-threatening manifestations. Conclusion: This living guideline will provide contemporary baseline immunosuppression recommendations for individuals with cancer and preexisting SARDs when initiating ICI therapy. New recommendations will be added over time and updated, with the latest recommendations, evidence summaries, and Evidence to Decision summaries available through the CRA and CanRIO websites ( www.rheum.ca , www.canrio.ca ). (PROSPERO registration: CRD42023461024)

15 September 2025 in The Journal of Rheumatology
Verified
Journal Article
Open access
PDF file
CYCarrie Ye
Carrie Ye
RNRoko P.A. Nikolic
Roko P.A. Nikolic
MCMay Choi
May Choi
AFAurore Viviane Fifi-Mah
Aurore Viviane Fifi-Mah
JGJeffrey Graham
Jeffrey Graham
SJShahin Jamal
Shahin Jamal
Objective: Immune checkpoint inhibitors (ICIs) are being increasingly used in patients with preexisting inflammatory arthritides (IAs). However, there are concerns that concomitant baseline immunosuppression at the time of ICI initiation may worsen cancer outcomes, a risk that needs to be balanced with the risk of IA flare. The objective of this study was to develop a living guideline that will offer up-to-date guidance on the management of baseline immunosuppression for preexisting IAs when initiating cancer immunotherapy with ICIs. Methods: The Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO) formed a multidisciplinary panel composed of rheumatologists, oncologists, researchers, and a patient representative, with methodological support from the Canadian Rheumatology Association (CRA). We completed a systematic literature review to inform this first installment of our living guideline. Using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach, the panel developed recommendations for the management of baseline immunosuppression in individuals with preexisting IAs. Results: We identified 67 relevant publications that reported on immunosuppression and cancer outcomes by specific preexisting rheumatic diseases, including 44 on preexisting IA. Eight best practice statements were developed, highlighting the importance of shared decision making between patients and their care team and careful consideration of risk of IA flare, risk of organ- or life-threatening manifestations, and the potential effect of immunosuppression on cancer outcomes. Four specific recommendations were made, one each for preexisting rheumatoid arthritis, polymyalgia rheumatica, psoriatic arthritis, and spondyloarthritis, considering both the available evidence and expert consensus. The general recommendation for preexisting IAs was to reduce or stop baseline immunosuppression, unless there are extraarticular organ- or life-threatening manifestations. Conclusion: This living guideline will provide contemporary baseline immunosuppression recommendations for individuals with cancer and preexisting IA when initiating ICI therapy. New recommendations will be added over time and updated, with the latest recommendations, evidence summaries, and Evidence to Decision summaries available through the CRA and CanRIO websites ( www.rheum.ca , www.canrio.ca ). (PROSPERO registration: CRD42023461024)